Overview
Theratechnologies is pepped up on peptides. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies received US approval for EGRIFTS in 2010 and approval in Canada and Mexico in 2015. The drug is marketed solely
...
Read More in the US (in partnership with inVentiv Health) and Canada. It is seeking to market EGRIFTA elsewhere around the world through partnerships with Sanofi, AOP Orphan Pharmaceuticals, and BL&H Co.
Read Less
Read More in the US (in partnership with inVentiv Health) and Canada. It is seeking to market EGRIFTA elsewhere around the world through partnerships with Sanofi, AOP Orphan Pharmaceuticals, and BL&H Co.
Read Less
Paul Lévesque
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Commercial physical research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$85.87 million
Actual
5.02%
$53
NOV
?
?
Toronto:TH
Contacts
Get in Touch with 11 Principals* and 40 Contacts
-
Paul LévesquePresident
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of November 30, 2024 (12 month period) in USD
Annual Revenue 2024
$85.87 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $2 | -$6 | -$15 |
| Net Investing Cash | $1 | $1 | $9 |
| Net Financing Cash | -$21 | $15 | $10 |
| Net Change in Cash | -$18 | $10 | $4 |
| Cash at Beginning of Period | $34 | $24 | $20 |
| Cash at End of Period | $16 | $34 | $24 |
| Capital Expenditure | -$2 | -$2 | -$1 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $6 | $34 | $24 |
| Accounts Receivable | $15 | $13 | $11 |
| Inventories | $5 | $6 | $20 |
| Other Current Assets | $18 | $10 | $19 |
| Asset Summary | |||
| Total Current Assets | $44 | $63 | $73 |
| Tangible Fixed Assets | $1 | $2 | $3 |
| Intangible Assets | $8 | $12 | $15 |
| Total Assets | $53 | $78 | $93 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $6 | $7 | $13 |
| Short-Term Debt | $3 | $7 | $65 |
| Other Current Liabilities | $27 | $33 | $37 |
| Liability Summary | |||
| Total Current Liabilities | $37 | $47 | $114 |
| Long-Term Debt | $41 | $51 | $ |
| Other Long-Term Liabilities | $0 | $0 | $ |
| Total Liabilities | $79 | $99 | $116 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $364 | $364 | $339 |
| Retained Earnings | -$417 | -$409 | -$383 |
| Equity Summary | |||
| Total Equity | -$25 | -$21 | -$23 |
| Shares Outstanding | 45,980,019 | 45,980,019 | 24,201,574 |